Figure 3: Pharmacogenetic analysis of toxicity and response.

(A) Characterisation of selected treatment-related adverse events in TYMS 3R/3R patients treated at 1,500 mg/m² during the first cycle or all cycles. (B) Per-cycle probability of a 65-year old individual on intermittent schedule capecitabine with TYMS 3R/3R genotype experiencing global grade ≥3 toxicity. Dashed curved lines represent 95% confidence interval. Dotted horizontal line represents cut-off probability, wherein maximum tolerable dose is declared if more than one of three patients experienced dose-limiting toxicities. (C) Relative change (%) in sum of target lesion size from baseline at best overall response in eighteen evaluable patients. Target lesions were not measured in 2 patients, and tumour assessment at the end of cycle 2 was not completed for 3 patients as a result of clinical deterioration or development of new lesions. Dotted lines indicate RECIST cut-off for partial response (−30%) and progressive disease (+20%). The TYMS genotype for patients are also annotated: 3R/3R (o), 2R/2R (#), 2R/3R (+). Abbreviations: HFS, hand-foot syndrome; PR, partial response; SD, stable disease; CD, clinical deterioration; PD, progressive disease; b.i.d., twice daily.